Novo Nordisk enters into collaboration with Danish crispr firm Snipr

The small Danish biotech company Snipr Biome, which uses crispr technology, has landed its first partnership.

Photo: Novo Nordisk / PR

Shortly after Snipr Biome managed to bring in new money through its first non-commercial partnership with antimicrobial alliance Carb-X, the Danish company has now managed to find its first commercial partner.

On Linkedin, Snipr states that it has started a collaboration with Novo Nordisk.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Related articles

Latest news

See all jobs